L-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy
Authors:
Open Access
- 20 December 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 23 (1) , 1-14
Abstract
In patients with type II diabetes, the development of diabetic cardiomyopathy (DC) is associated with a high risk of mortality. Left ventricular hypertrophy, diastolic dysfunction, and exercise intolerance are the first signs of DC. The underlying mechanisms are not fully elucidated, and there is an urgent need for specific biomarkers and molecular targets for early diagnosis and treatment. Mitochondrial alterations play a key role in the development of DC, and microRNAs regulating mitochondrial function are emerging as potential biomarkers of metabolic stress in DC. L-Arginine (Arg) supplementation has been shown to be an effective strategy for improving mitochondrial function and energetics, with a significant impact on physical performance. The aim of the current study was to evaluate the effects of Arg supplementation on cardiac mitochondrial function, DC development, and relative phenotypes including exercise intolerance. We used db/db mice as a model of type II diabetes, chronically treated with Arg (1 mg/kg/day) for 12 weeks. Arg-treated db/db mice showed preserved diastolic function and left ventricular morphology compared with untreated diabetic mice. Arg supplementation also improved exercise tolerance and the propensity to physical activity. Mitochondrial respiration was significantly increased in cardiomyocytes isolated from treated db/db mice, as well as in diabetic cardiomyocytes treated with Arg in vitro. The improvement of cardiac mitochondrial function in db/db + Arg mice was associated with an increase in PGC-1-alpha levels, mitochondrial biogenesis, recycling, and antioxidant capacity. Arg treatment prevented the accumulation of circulating and cardiac miR-143 in db/db mice, which is an index of metabolic stress and activation of mitochondrial damage mechanisms. In conclusion, Arg supplementation is effective in preventing the development of DC, preserving diastolic function and exercise tolerance by improving mitochondrial fitness and homeostasis. Additionally, miR-143 could potentially be employed to monitor cardiac metabolic stress and the effects of Arg treatment in diabetes.Keywords
Funding Information
- PNRR NGUE- PE8 Age.it ((E63C22002050006).)
- Ministero dell’Istruzione, dell’Università e della Ricerca (Next Generation EU, National Recovery and Resilience Plan, Investment PE8—Project Age-It: “Ageing Well in an Ageing Society”.)
- European Commission (PON “REACT-E U” IV.4 action 2014–2020)
This publication has 65 references indexed in Scilit:
- MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modellingDiabetologia, 2022
- MicroRNA-143 promotes cardiac ischemia-mediated mitochondrial impairment by the inhibition of protein kinase CepsilonBasic Research in Cardiology, 2017
- Mitochondrial dysfunction and its impact on diabetic heartBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2017
- Integrating GRK2 and NFkappaB in the Pathophysiology of Cardiac HypertrophyJournal of Cardiovascular Translational Research, 2015
- Novel metabolic roles of L-arginine in body energy metabolism and possible clinical applicationsThe Journal of nutrition, health and aging, 2014
- Analysis and Interpretation of Microplate-Based Oxygen Consumption and pH Data2014
- Mitochondrial dysfunction in diabetic cardiomyopathyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Mitochondrial dysfunction and lipotoxicityBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- Transcriptional Control of Energy Homeostasis through the PGC1 Coactivators2007
- Transcriptional Control of Mitochondrial Energy Metabolism through the PGC1 Coactivators2007